箱庭疗法联合氟西汀对轻中度抑郁症伴失眠患者的疗效分析

Effect of sandplay therapy combined with fluoxetine on patients with mild to moderate depression and insomnia

摘要:

目的 分析箱庭疗法联合氟西汀对轻中度抑郁症伴失眠患者的疗效。方法 选取2017年8月—2018年8月徐州市东方人民医院收治的80例轻中度抑郁症伴失眠患者，应用简单随机化法将其分为研究组和对照组，对照组给予口服氟西汀治疗，研究组给予箱庭疗法联合氟西汀治疗，均治疗8周。对比治疗前后两组汉密尔顿抑郁量表（HAMD）评分、匹兹堡睡眠质量指数量表（PSQI）评分及日间功能障碍评分。治疗结束后评估并对比两组临床疗效，统计两组治疗期间不良反应发生情况。结果 研究组治疗前后HAMD、PSQI和日间功能障碍评分差值均大于对照组（P <0.05）。研究组总有效率为92.50%高于对照组的75.00%（P <0.05）。两组食欲不振、口干便秘等不良反应发生率及总不良反应发生率比较，差异无统计学意义（P >0.05）。结论 箱庭疗法联合氟西汀可显著改善轻中度抑郁症伴失眠症患者抑郁及失眠症状，临床疗效确切，安全可靠。

Abstract:

Objective To analyze the efficacy of sandplay therapy combined with fluoxetine in patients with mild to moderate depression and insomnia.Methods A total of 80 patients with mild to moderate depression and insomnia admitted to Xuzhou Oriental People's Hospital from August 2017 to August 2018 were selected and randomly divided into study group and control group. The control group was treated with fluoxetine alone, and the study group was treated with sandplay therapy and fluoxetine. The treatment course was 8 weeks for both groups. The Hamilton Depression Rating Scale (HAMD) score, the Pittsburgh Sleep Quality Index (PSQI) score, and the daytime dysfunction score before and after treatment of the two groups were compared. After treatment, the therapeutic efficacy was evaluated and compared between the groups. The incidence of adverse reactions during the treatment was also recorded.Results The score differences of HAMD, PSQI and daytime dysfunction before and after treatment in the study group were higher than those in the control group (P < 0.05). The overall effective rate in the study group (92.50%) was higher than that of the control group (75.00%). There was no significant difference in the incidence of anorexia, dry mouth, constipation or other adverse reactions between the two groups (P > 0.05).Conclusions Sandplay therapy combined with fluoxetine can significantly improve the clinical symptoms in patients with mild to moderate depression and insomnia, with obvious clinical efficacy and safety.